Patents by Inventor SukRan Yoon

SukRan Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of differentiating hematopoietic stem cells into natural killer cells using YC-1 or IL-21
    Patent number: 8318491
    Abstract: The present invention relates to an agent for differentiating hematopoietic stem cells into natural killer cells and a method for the differentiation, more precisely an agent for differentiating hematopoietic stem cells into natural killer cells comprising YC-I [3-(5?-hydroxymethyl-2?-furyl)-1-benzylindazole] or IL-21 (Interleukin-21) as an active ingredient and a method for differentiating hematopoietic stem cells into natural killer cells using the same. The YC-I and IL-21 regulate the differentiation of hematopoietic stem cells into natural killer cells and increase the killing activity of NK cells. Therefore, the agent for NK cell differentiation of the present invention can be effectively used for cell therapy for the treatment of cancer by regulating the differentiation of hematopoietic stem cells into natural killer cells having tumor cell killing activity.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: November 27, 2012
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Inpyo Choi, SukRan Yoon, Sohyun Yun, Jin Woong Chung
  • AGENT FOR DIFFERENTIATING HEMATOPOIETIC STEM CELL INTO NATURAL KILLER CELL COMPRISING YC-1 OR IL-2 1 AND A METHOD OF DIFFERENTIATING HEMATOPOIETIC STEM CELL INTO NATURAL KILLER CELL USING THE SAME
    Publication number: 20110033415
    Abstract: The present invention relates to an agent for differentiating hematopoietic stem cells into natural killer cells and a method for the differentiation, more precisely an agent for differentiating hematopoietic stem cells into natural killer cells comprising YC-I [3-(5?-hydroxymethyl-2?-furyl)-1-benzylindazole] or IL-21 (Interleukin-21) as an active ingredient and a method for differentiating hematopoietic stem cells into natural killer cells using the same. The YC-I and IL-21 regulate the differentiation of hematopoietic stem cells into natural killer cells and increase the killing activity of NK cells. Therefore, the agent for NK cell differentiation of the present invention can be effectively used for cell therapy for the treatment of cancer by regulating the differentiation of hematopoietic stem cells into natural killer cells having tumor cell killing activity.
    Type: Application
    Filed: October 2, 2007
    Publication date: February 10, 2011
    Inventors: Inpyo Choi, SukRan Yoon, Sohyun Yun, Jin Woong Chung
  • Agent for Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Comprising Vdup1 Protein or Gene Encoding the Same, and a Method of Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Using Thereof
    Publication number: 20090042188
    Abstract: The present invention is related to an agent for differentiating hematopoietic stem cell into natural killer cell comprising VDUP1 protein or gene encoding the same, and a method of differentiating hematopoietic stem cell into natural killer cell using thereof. The present invention reveals for the first time that the VDUP1 gene is a critical factor for the regulation of differentiation of natural killer cell by generating a mouse deficient in VDUP1 gene, which confirms that VDUP1 gene is required for NK maturation. Thus, through the regulation of VDUP1 gene, the modulation of NK cells that have ability to kill cancer cells is possible and can be utilized for cell therapeutics.
    Type: Application
    Filed: June 8, 2005
    Publication date: February 12, 2009
    Applicant: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Inpyo Choi, SukRan Yoon, KeeNyung Lee, SunWook Kim, DaeYul Yoo